Characterization of MET exon 14 skipping alterations (METex14) in non-small cell lung cancer (NSCLC) using whole transcriptome sequencing (WTS) | Caris Life Sciences
Portal
Order

MI Cancer Seek™ is now available for clinical ordering. Learn more.

Home / Research / Publications / Characterization of MET exon 14 skipping alterations (METex14) in non-small cell lung cancer (NSCLC) using whole transcriptome sequencing (WTS)

Publications

Back

Characterization of MET exon 14 skipping alterations (METex14) in non-small cell lung cancer (NSCLC) using whole transcriptome sequencing (WTS)

– Caris Life Sciences

Poster

Key Finding:

In non-small cell lung cancer, splicing alterations and MET co-amplification result in high MET expression. 

Download Publication

Discover
More

  • Loss of O6-Methylguanine-DNA Methyltransferase Protein Expression by Immunohistochemistry Is Associated With Response to Capecitabine and Temozolomide in Neuroendocrine Neoplasms

    – Caris Life Sciences

    Manuscript

    Abstract Background A recent prospective phase II study (ECOG-ACRIN E2211) demonstrated that MGMT deficiency was associated with a significant response to capecitabine and temozolomide (CAPTEM)… […]

  • Clinical and Molecular Characterization of FAP and SPP1 in Colorectal Cancer (CRC), CALGB (Alliance)/SWOG 80405 and Real-world Data

    – Caris Life Sciences

    Poster

    Background […]
Learn More

Ready to Get Started on the Journey?

Name(Required)